1. Жиров И.В., Насонова С.Н., Халилова У.А., и др. Острая декомпенсация сердечной недостаточности. Что изменилось в клинических рекомендациях в 2021 году? Consilium Medicum. 2022;24(1):7-12 [Zhirov IV, Nasonova SN, Khalilova UA, et al. Acute decompensated heart failure. What has changed in the clinical guidelines in 2021? Consilium Medicum. 2022;24(1):7-12 (in Russian)]. DOI:10.26442/20751753.2022.1.201410
2. Kashyap R, Sarvottam K, Wilson GA, et al. Derivation and validation of a computable phenotype for acute decompensated heart failure in hospitalized patients. BMC Med Inform Decis Mak. 2020;20(1):85. DOI:10.1186/s12911-020-1092-5
3. Смирнова Е.А., Седых Е.В., Якушин С.С., Субботин С.В. Распространенность и клиническое значение дефицита железа у пациентов с острой декомпенсацией сердечной недостаточности. Российский кардиологический журнал. 2023;28(8):5413 [Smirnova EA, Sedykh EV, Yakushin SS, Subbotin SV. Prevalence and clinical significance of iron deficiency in patients with acute decompensated heart failure. Russian Journal of Cardiology. 2023;28(8):5413 (in Russian)]. DOI:10.23888/HMJ202192289-300
4. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18(5):858-65. DOI:10.1093/oxfordjournals.eurheartj.a015352
5. Doehner W, Rauchhaus M, Florea VG, et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J. 2001;141(5):792-9. DOI:10.1067/mhj.2001.114367
6. Pina AF, Borges DO, Meneses MJ, et al. Insulin: Trigger and Target of Renal Functions. Front Cell Dev Biol. 2020;8:519. DOI:10.3389/fcell.2020.00519
7. Waheed Y, Yang F, Sun D. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. Korean J Intern Med. 2021;36(6):1281-93. DOI:10.3904/kjim.2020.340
8. Ледяхова М.В., Насонова С.Н., Терещенко С.Н. Гиперурикемия как предиктор хронической сердечной недостаточности. Рациональная Фармакотерапия в Кардиологии. 2015;11(4):355-8 [Ledyakhova MV, Nasonova SN, Tereshchenko SN. Hyperuricemia as a predictor of chronic heart failure. Rational Pharmacotherapy in Cardiology. 2015;11(4):355-8 (in Russian)]. DOI:10.20996/1819-6446-2015-11-4-355-358
9. Tamariz L, Harzand A, Palacio A, et al. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail. 2011;17(1):25-30.
DOI:10.1111/j.1751-7133.2011.00200.x
10. Deng H, Zhang X, Cheng N, et al. Asymptomatic hyperuricemia associated with increased risk of  nephrolithiasis: a cross-sectional study. BMC Public Health. 2023;23(1):1525. DOI:10.1186/s12889-023-16469-y
11. Чазова И.Е., Жернакова Ю.В., Кисляк О.А., и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022. Системные гипертензии. 2022;19(1):5-22 [Chazova IE, Zhernakova YuV, Kislyak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5-22 (in Russian)]. DOI:10.38109/2075-082X-2022-1-5-22
12. Vaduganathan M, Greene SJ, Ambrosy AP, et al. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014;114(11):1713-21. DOI:10.1016/j.amjcard.2014.09.008
13. Huang G, Qin J, Deng X, et al. Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis. Medicine (Baltimore). 2019;98(8):e14525. DOI:10.1097/MD.0000000000014525
14. Bielecka-Dabrowa A, Godoy B, Schefold JC, et al. Decompensated Heart Failure and Renal Failure: What Is the Current Evidence? Curr Heart Fail Rep. 2018;15(4):224-38. DOI:10.1007/s11897-018-0397-5
15. Llauger L, Espinosa B, Rafique Z, et al. Impact of worsening renal function detected at emergency department arrival on acute heart failure short-term outcomes. Eur J Emerg Med. 2023;30(2):91-101. DOI:10.1097/MEJ.0000000000001016
16. Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia. 2016;8(2):56-61.
DOI:10.1136/heartasia-2016-010809
17. Эбзеева Е.Ю., Де В.А., Ни Л.И., и др. Хроническая болезнь почек и артериальная гипертензия: как разорвать порочный круг? РМЖ. 2022;5:30-4 [Ebzeeva EYu,De VA,Ni LI, et al. Chronic kidney disease and hypertension: How to break the vicious circle? Russian Medical Journal. 2022;5:30-4 (in Russian)].
18. Щербак А.В., Козловская Л.В., Бобкова И.Н., и др. Гиперурикемия и проблема хронической болезни почек. Терапевтический архив. 2013;85(6):100-4 [Shcherbak AV, Kozlovskaya LV, Bobkova IN, et al. Hyperuricemia and the problem of chronic kidney disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2013;85(6):100-4 (in Russian)].
19. Feig DI. Uric acid and hypertension. Semin Nephrol. 2011;31(5):441-6. DOI:10.1016/j.semnephrol.2011.08.008
20. Миронова О.Ю. Гиперурикемия: современные особенности терапии у пациентов с сердечно-сосудистыми заболеваниями. Евразийский Кардиологический Журнал. 2022;(2):72-8 [Mironova O.Yu. Hyperuricemia: contemporary treatment in patients with cardiovascular disease. Eurasian Heart Journal. 2022;(2):72-8 (in Russian)].
DOI:10.38109/2225-1685-2022-2-72-78
21. Барсуков А.В., Борисова Е.В., Дыдышко В.Т., Наумкина П.И. Сердечная недостаточность и уратснижающая терапия: клинические аспекты. Университетский терапевтический вестник. 2022;4(4):16-28 [Barsukov AV, Borisova EV, Dydyshko VT, Naumkina PI. Heart failure and urate-lowering therapy: Clinical aspects. University Therapeutic Journal. 2022;4(4):16-28 (in Russian)]. DOI:10.56871/3999.2022.69.27.002
22. Nishino M, Egami Y, Kawanami S, et al. Lowering Uric Acid May Improve Prognosis in Patients With Hyperuricemia and Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2022;11(19):e026301. DOI:10.1161/JAHA.122.026301
23. Beattie CJ, Fulton RL, Higgins P, et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension.
2014;64(5):1102-7. DOI:10.1161/HYPERTENSIONAHA.114.03953
24. Jennings CG, Mackenzie IS, Flynn R, et al. Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum. 2014;44(1):25-30. DOI:10.1016/j.semarthrit.2014.01.004
25. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/ day in patients with gout. Ann Rheum Dis. 2009;68(6):892-7. DOI:10.1136/ard.2008.091462
26. Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015;45(2):174-83. DOI:10.1016/j.semarthrit.2015.05.005
27. Stamp LK, Chapman PT, Barclay M, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Ann Rheum Dis. 2017;76(12):2065-70. 
DOI:10.1136/annrheumdis-2017-211873
28. Ассоциация ревматологов России. Подагра: клинические рекомендации. 2018. Режим доступа: http://cr.rosminzdrav.ru/recomend/251_1. Ссылка активна на 01.09.2022 [Assotsiatsiia revmatologov Rossii. Podagra: klinicheskie rekomendatsii. 2018. Available at: http://cr.rosminzdrav.ru/recomend/251_1. Accessed: 01.09.2022 (in Russian)].
29. Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458-62. DOI:10.1111/dom.13101
30. Паневин Т.С., Елисеев М.С., Шестакова М.В., Насонов Е.Л. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2-го типа у пациентов с сахарным диабетом 2-го типа в сочетании с гиперурикемией и подагрой. Терапевтический архив. 2020;92(5):110-8 [Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(5):110-8 (in Russian)]. DOI:0.26442/00403660.2020.05.000633

________________________________________________

1. Zhirov IV, Nasonova SN, Khalilova UA, et al. Acute decompensated heart failure. What has changed in the clinical guidelines in 2021? Consilium Medicum. 2022;24(1):7-12 (in Russian). DOI:10.26442/20751753.2022.1.201410
2. Kashyap R, Sarvottam K, Wilson GA, et al. Derivation and validation of a computable phenotype for acute decompensated heart failure in hospitalized patients. BMC Med Inform Decis Mak. 2020;20(1):85. DOI:10.1186/s12911-020-1092-5
3. Smirnova EA, Sedykh EV, Yakushin SS, Subbotin SV. Prevalence and clinical significance of iron deficiency in patients with acute decompensated heart failure. Russian Journal of Cardiology. 2023;28(8):5413 (in Russian). DOI:10.23888/HMJ202192289-300
4. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18(5):858-65. DOI:10.1093/oxfordjournals.eurheartj.a015352
5. Doehner W, Rauchhaus M, Florea VG, et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J. 2001;141(5):792-9. DOI:10.1067/mhj.2001.114367
6. Pina AF, Borges DO, Meneses MJ, et al. Insulin: Trigger and Target of Renal Functions. Front Cell Dev Biol. 2020;8:519. DOI:10.3389/fcell.2020.00519
7. Waheed Y, Yang F, Sun D. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. Korean J Intern Med. 2021;36(6):1281-93. DOI:10.3904/kjim.2020.340
8. Ledyakhova MV, Nasonova SN, Tereshchenko SN. Hyperuricemia as a predictor of chronic heart failure. Rational Pharmacotherapy in Cardiology. 2015;11(4):355-8 (in Russian). DOI:10.20996/1819-6446-2015-11-4-355-358
9. Tamariz L, Harzand A, Palacio A, et al. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail. 2011;17(1):25-30.
DOI:10.1111/j.1751-7133.2011.00200.x
10. Deng H, Zhang X, Cheng N, et al. Asymptomatic hyperuricemia associated with increased risk of  nephrolithiasis: a cross-sectional study. BMC Public Health. 2023;23(1):1525. DOI:10.1186/s12889-023-16469-y
11. Chazova IE, Zhernakova YuV, Kislyak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5-22 (in Russian). DOI:10.38109/2075-082X-2022-1-5-22
12. Vaduganathan M, Greene SJ, Ambrosy AP, et al. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014;114(11):1713-21. DOI:10.1016/j.amjcard.2014.09.008
13. Huang G, Qin J, Deng X, et al. Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis. Medicine (Baltimore). 2019;98(8):e14525. DOI:10.1097/MD.0000000000014525
14. Bielecka-Dabrowa A, Godoy B, Schefold JC, et al. Decompensated Heart Failure and Renal Failure: What Is the Current Evidence? Curr Heart Fail Rep. 2018;15(4):224-38. DOI:10.1007/s11897-018-0397-5
15. Llauger L, Espinosa B, Rafique Z, et al. Impact of worsening renal function detected at emergency department arrival on acute heart failure short-term outcomes. Eur J Emerg Med. 2023;30(2):91-101. DOI:10.1097/MEJ.0000000000001016
16. Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia. 2016;8(2):56-61.
DOI:10.1136/heartasia-2016-010809
17. Ebzeeva EYu,De VA,Ni LI, et al. Chronic kidney disease and hypertension: How to break the vicious circle? Russian Medical Journal. 2022;5:30-4 (in Russian).
18. Shcherbak AV, Kozlovskaya LV, Bobkova IN, et al. Hyperuricemia and the problem of chronic kidney disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2013;85(6):100-4 (in Russian).
19. Feig DI. Uric acid and hypertension. Semin Nephrol. 2011;31(5):441-6. DOI:10.1016/j.semnephrol.2011.08.008
20. Mironova O.Yu. Hyperuricemia: contemporary treatment in patients with cardiovascular disease. Eurasian Heart Journal. 2022;(2):72-8 (in Russian).
DOI:10.38109/2225-1685-2022-2-72-78
21. Barsukov AV, Borisova EV, Dydyshko VT, Naumkina PI. Heart failure and urate-lowering therapy: Clinical aspects. University Therapeutic Journal. 2022;4(4):16-28 (in Russian). DOI:10.56871/3999.2022.69.27.002
22. Nishino M, Egami Y, Kawanami S, et al. Lowering Uric Acid May Improve Prognosis in Patients With Hyperuricemia and Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2022;11(19):e026301. DOI:10.1161/JAHA.122.026301
23. Beattie CJ, Fulton RL, Higgins P, et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension.
2014;64(5):1102-7. DOI:10.1161/HYPERTENSIONAHA.114.03953
24. Jennings CG, Mackenzie IS, Flynn R, et al. Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum. 2014;44(1):25-30. DOI:10.1016/j.semarthrit.2014.01.004
25. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/ day in patients with gout. Ann Rheum Dis. 2009;68(6):892-7. DOI:10.1136/ard.2008.091462
26. Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015;45(2):174-83. DOI:10.1016/j.semarthrit.2015.05.005
27. Stamp LK, Chapman PT, Barclay M, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Ann Rheum Dis.
2017;76(12):2065-70. DOI:10.1136/annrheumdis-2017-211873
28. Assotsiatsiia revmatologov Rossii. Podagra: klinicheskie rekomendatsii. 2018. Available at: http://cr.rosminzdrav.ru/recomend/251_1. Accessed: 01.09.2022 (in Russian).
29. Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458-62. DOI:10.1111/dom.13101
30. Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(5):110-8 (in Russian). DOI:0.26442/00403660.2020.05.000633

Л.Х. Сариева*¹, С.Н. Насонова¹, И.В. Жиров^1,2, И.А. Жирова³, С.Н. Терещенко<sup>1

1</sup>ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия;
²ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
³ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы», Москва, Россия
*laur.sarieva@yandex.ru

________________________________________________

Laura H. Sarieva*¹, Svetlana N. Nasonova¹, Igor V. Zhirov^1,2, Irina A. Zhirova³, Sergey N. Tereshchenko<sup>1

1</sup>Chazov National Medical Research Center of Cardiology, Moscow, Russia;
²Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
³Patrice Lumumba People’s Friendship University of Russia, Moscow, Russia
*laur.sarieva@yandex.ru